Singaporean startup Respiree will get US FDA 510(ok) for respiration monitor

Respiree, a med tech spinoff of Singapore’s Company for Science, Know-how and Analysis, has obtained the US Meals and Drug Administration’s 510(ok) clearance for its wearable cardio-respiratory sensor system. 

The RS001 system immediately measures respiration in sufferers coping with cardio-pulmonary ailments corresponding to COPD and congestive coronary heart failure.

It’s a part of Respiree’s iRIS Related Care Platform the place it’s used to remotely measure important parameters, together with respiratory price, coronary heart price, SpO2, temperature, and physiologic indicators corresponding to tidal quantity and obligation cycle. 

After securing such a significant clearance, Respiree will search additional approval for the system’s expanded indication to be used and software program. RS001 has additionally been cleared in each Europe and Australia after getting respective clearances.


COPD impacts an estimated 200 million folks worldwide. It’s recognized to be the third deadliest illness globally, claiming 3.2 million lives every year, based on the WHO. This excessive illness burden is claimed to be pushed by exacerbations or worsening circumstances in sufferers.

“COPD exacerbations drive each morbidity and mortality. You will need to be capable of determine them early and stop them with the appropriate therapeutic,” mentioned Respiree CEO and founder Dr Gurpreet Singh.

Respiree’s wearable sensor system helps on this endeavour by figuring out COPD exacerbations “not hours or minutes prematurely, however days prematurely,” Dr Singh famous.


The wearable sensor system can also be a part of a distant affected person monitoring system which Respiree developed with Changi Basic Hospital. Late final yr, they introduced that they’re validating AI algorithms for predicting affected person deterioration as a part of the mentioned RPM system.

10 Bubble Tea Franchise Alternatives in 2023

How What You Eat Fuels Your Enterprise Success